|
|
|
Insider
Information: |
Sachdev Amit |
Relationship: |
|
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
71,325 |
|
Indirect Shares
|
7,447 |
|
|
Direct
Value |
$26,276,609 |
|
|
Indirect Value
|
$3,536,953 |
|
|
Total
Shares |
78,772 |
|
|
Total
Value |
$29,813,561 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP Chief Patient & Ex... |
2024-05-15 |
55,325 |
2024-05-15 |
7,447 |
Premium* |
|
Celladon Corp |
CLDN |
|
2022-03-11 |
16,000 |
2020-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
193 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 6 of 8
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2020-02-24 |
4 |
D |
$239.23 |
$755,010 |
D/D |
(3,156) |
36,291 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2021-02-10 |
4 |
D |
$214.16 |
$518,481 |
D/D |
(2,421) |
68,002 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2021-02-17 |
4 |
D |
$211.75 |
$1,612,053 |
D/D |
(7,613) |
55,929 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2021-02-24 |
4 |
D |
$217.57 |
$640,961 |
D/D |
(2,946) |
43,719 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2022-02-10 |
4 |
D |
$237.74 |
$592,210 |
D/D |
(2,491) |
59,075 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2022-02-17 |
4 |
D |
$232.51 |
$813,087 |
D/D |
(3,497) |
55,578 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2022-02-24 |
4 |
D |
$227.86 |
$1,678,872 |
D/D |
(7,368) |
48,210 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2023-02-10 |
4 |
D |
$294.33 |
$768,496 |
D/D |
(2,611) |
77,141 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2023-02-13 |
4 |
D |
$298.26 |
$1,388,997 |
D/D |
(4,657) |
72,484 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,024,389 |
D/D |
(3,498) |
68,986 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2023-02-24 |
4 |
D |
$289.12 |
$713,548 |
D/D |
(2,468) |
66,518 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
|
2024-02-09 |
4 |
D |
$422.74 |
$854,780 |
D/D |
(2,022) |
77,586 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
|
2024-02-16 |
4 |
D |
$424.01 |
$1,483,187 |
D/D |
(3,498) |
70,866 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
|
2024-02-20 |
4 |
D |
$420.58 |
$1,103,181 |
D/D |
(2,623) |
68,243 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP Chief Patient & Ext Af Off |
|
2024-02-23 |
4 |
D |
$431.79 |
$1,066,090 |
D/D |
(2,469) |
58,329 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2020-12-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,391 |
7,368 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Patient Officer |
|
2022-05-17 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,672 |
11,052 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2011-01-18 |
4 |
OE |
$18.93 |
$225,532 |
D/D |
11,914 |
51,752 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2011-02-23 |
4 |
OE |
$18.93 |
$451,064 |
D/D |
23,828 |
67,954 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2011-02-28 |
4 |
OE |
$18.93 |
$225,551 |
D/D |
11,915 |
56,041 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2011-03-03 |
4 |
OE |
$18.93 |
$180,422 |
D/D |
9,531 |
49,685 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2012-03-30 |
4 |
OE |
$18.93 |
$360,844 |
D/D |
19,062 |
60,170 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2012-05-07 |
4 |
OE |
$29.25 |
$1,645,313 |
D/D |
56,250 |
89,858 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2012-09-13 |
4 |
OE |
$29.25 |
$854,954 |
D/D |
28,281 |
59,389 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
SVP, Corp Affairs & Pub Policy |
|
2012-09-14 |
4 |
OE |
$32.16 |
$306,517 |
D/D |
9,531 |
30,639 |
0 |
- |
|
193 Records found
|
|
Page 6 of 8 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|